Ultragenyx Pharmaceutical (RARE) Raised to Hold at BidaskClub
BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a sell rating to a hold rating in a research note issued to investors on Wednesday.
RARE has been the topic of a number of other reports. Canaccord Genuity set a $80.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a report on Thursday, November 16th. Robert W. Baird dropped their target price on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an outperform rating on the stock in a report on Friday, November 3rd. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, October 25th. Morgan Stanley reiterated an equal weight rating and issued a $71.00 price target (up previously from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Finally, Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 17th. They issued an outperform rating and a $67.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $72.06.
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $56.84 on Wednesday. The stock has a market cap of $2,714.49, a PE ratio of -8.15 and a beta of 1.83. Ultragenyx Pharmaceutical has a fifty-two week low of $43.14 and a fifty-two week high of $91.35.
Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $156,000. Kazazian Asset Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $213,000. Fox Run Management L.L.C. acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $213,000. Ameritas Investment Partners Inc. grew its position in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares in the last quarter. Finally, Amalgamated Bank grew its position in shares of Ultragenyx Pharmaceutical by 7.6% during the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares in the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.